Urolithin A healthspan signals

Urolithin A is a compound linked to cellular cleanup, and human trials have tied it to better muscle endurance, lower inflammation markers, and some gains in strength. (cell.com) (jamanetwork.com) Cells use mitochondria the way engines use fuel, and mitophagy is the recycling system that removes worn-out mitochondria before they clog the system. Urolithin A is a metabolite made when gut microbes process ellagitannins and ellagic acid from foods such as pomegranate, berries, and nuts. (sciencedirect.com) (pmc.ncbi.nlm.nih.gov) That cleanup process tends to weaken with age, especially in muscle, where damaged mitochondria are linked to fatigue, lower exercise capacity, and slower recovery. Reviews published in 2023 and 2024 describe mitochondrial dysfunction and chronic inflammation as recurring features of age-related muscle decline. (pmc.ncbi.nlm.nih.gov) (springer.com) The strongest human evidence so far comes from randomized, placebo-controlled trials rather than a single clinic write-up. In a January 2022 JAMA Network Open trial, 66 adults ages 65 to 90 took 1,000 milligrams of urolithin A or placebo daily for four months in Seattle. (jamanetwork.com) That study did not find a significant improvement in its primary endpoints, which were six-minute walk distance and maximal adenosine triphosphate production in hand muscle. It did find significant improvement in muscle endurance tests for both hand and leg muscles, along with lower blood levels of acylcarnitines, ceramides, and C-reactive protein. (jamanetwork.com) (pmc.ncbi.nlm.nih.gov) A second placebo-controlled trial published in 2022 in Cell Reports Medicine studied middle-aged adults and reported improvements in leg and hand muscle strength, aerobic endurance, and exercise performance after oral supplementation. The paper describes those changes alongside shifts in biomarkers tied to mitophagy and mitochondrial metabolism. (cell.com) (nature.com) Those trial results are the basis for claims that strength rose by about 12 percent and inflammation fell, but the exact effect size depends on the study population, dose, endpoint, and test used. The published literature is more precise than social posts: some endpoints improved, some did not, and the evidence is strongest for muscle function and biomarker changes over a few months. (cell.com) (jamanetwork.com) The neurodegeneration angle is earlier-stage. Reviews and animal or cell studies describe links between impaired mitophagy, neuroinflammation, and disorders such as Parkinson’s disease and Alzheimer’s disease, but those findings are not the same as showing clinical benefit in people with those diseases. (nature.com) (mdpi.com) Human research is still moving in that direction. ClinicalTrials.gov lists a randomized placebo-controlled study, updated on February 19, 2026, that plans to test 500 milligrams daily for 24 weeks in about 100 adults with obesity while tracking muscle function, inflammation, and mitochondrial markers. (clinicaltrials.gov) Safety data in published trials have generally been reassuring over short study periods. The 2022 JAMA trial said urolithin A was safe and well tolerated, but longer-term outcomes and disease-specific effects still need larger trials. (jamanetwork.com) (pmc.ncbi.nlm.nih.gov) So the cleanest read on the evidence is narrower than the hype: urolithin A has human trial signals in muscle endurance, some strength measures, and inflammation-related biomarkers, while the broader longevity and brain-health claims are still being tested. (cell.com) (pmc.ncbi.nlm.nih.gov)